WallStSmart
MCRB

Seres Therapeutics Inc

NASDAQ: MCRB · HEALTHCARE · BIOTECHNOLOGY

$7.05
-0.56% today

Updated 2026-04-29

Market cap
$67.91M
P/E ratio
11.02
P/S ratio
86.07x
EPS (TTM)
$0.64
Dividend yield
52W range
$7 – $30
Volume
0.1M

WallStSmart proprietary scores

35
out of 100
Grade: D
Sell
Investment rating
2.0
Growth
F
5.0
Quality
C+
5.5
Profitability
C+
6.7
Valuation
B
4/9
Piotroski F-Score
Moderate
-12.0
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$22.00
+212.06%
12-Month target
$7.31
+3.69%
Intrinsic (DCF)
Margin of safety
0 Strong Buy1 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Profit margin 722.00% — above average
Risks
- Altman Z -11.96 — distress zone
- Negative free cash flow $-14.74M
- Revenue declining -93.40% QoQ

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$7.13M$126.33M$0.00$789000.00$789000.00
Net income$-250.16M$-113.72M$136000.00$5.70M$-15.34M
EPS$0.64
Free cash flow$-238.64M$-125.33M$-148.99M$865000.00$-14.74M
Profit margin-3,509.50%-90.02%721.93%722.00%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
MCRB$67.91M352.05.56.75.0Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

Seres Therapeutics Inc trades at $7.05. representing a P/E of 11.02x trailing earnings. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -11.96, it sits in the distress. TTM revenue stands at $789000.00. with profit margins at 722.00%.

Frequently asked questions

What is Seres Therapeutics Inc's stock price?
Seres Therapeutics Inc (MCRB) trades at $7.05.
Is Seres Therapeutics Inc overvalued?
Smart Value Score 35/100 (Grade D, Sell).
What is the price target of Seres Therapeutics Inc (MCRB)?
The analyst target price is $22.00, representing +212.1% upside from the current price of $7.05.
What is Seres Therapeutics Inc's revenue?
TTM revenue is $789000.00.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-11.96 — distress.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio86.07x
ROE19.60%
Beta0.26
50D MA$8.70
200D MA$14.56
Shares out0.01B
Float0.01B
Short ratio
Avg volume0.1M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years